IRLAB Therapeutics AB

IRLAB Therapeutics AB is a pioneering biotechnology research company dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, particularly Parkinson's disease. With a focus on addressing the most challenging symptoms, IRLAB Therapeutics AB is committed to improving the lives of patients through its cutting-edge research and clinical development programs.

IRLAB Therapeutics AB's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are currently in Phase IIb clinical trials, targeting the most debilitating symptoms associated with Parkinson's. The company's proprietary systems biology-based Integrative Screening Process (ISP) research platform enables the discovery of novel drug candidates. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam, showcasing the strength and potential of IRLAB Therapeutics AB's innovations.

Located at Arvid Wallgrens Backe 20, Göteborg, 41346, SE, IRLAB Therapeutics AB continues to advance its preclinical programs, IRL942 and IRL757, towards Phase I studies, reinforcing its commitment to long-term growth and innovation in the biotechnology sector. We invite the manager of IRLAB Therapeutics AB to create a customized and exclusive company showcase and product listing on our platform to further enhance your market presence and commercial opportunities.